146.435 USD
+0.88 (+0.61%)
Taking everything into account, ILMN scores 5 out of 10 in our fundamental rating. ILMN was compared to 57 industry peers in the Life Sciences Tools & Services industry. While ILMN belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. ILMN has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year ILMN was profitable.
In the past year ILMN had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: ILMN reported negative net income in multiple years.
Each year in the past 5 years ILMN had a positive operating cash flow.
1.2 Ratios
ILMN has a better Return On Assets (11.38%) than 91.23% of its industry peers.
Looking at the Return On Equity, with a value of 29.53%, ILMN belongs to the top of the industry, outperforming 96.49% of the companies in the same industry.
ILMN has a better Return On Invested Capital (16.40%) than 91.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.38% | ||
| ROE | 29.53% | ||
| ROIC | 16.4% |
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 16.39%, ILMN belongs to the best of the industry, outperforming 89.47% of the companies in the same industry.
Looking at the Operating Margin, with a value of 20.41%, ILMN belongs to the top of the industry, outperforming 85.96% of the companies in the same industry.
In the last couple of years the Operating Margin of ILMN has declined.
With an excellent Gross Margin value of 66.74%, ILMN belongs to the best of the industry, outperforming 87.72% of the companies in the same industry.
ILMN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.41% | ||
| PM (TTM) | 16.39% | ||
| GM | 66.74% |
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
2. Health
2.1 Basic Checks
ILMN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, ILMN has about the same amount of shares outstanding.
Compared to 5 years ago, ILMN has more shares outstanding
ILMN has a worse debt/assets ratio than last year.
2.2 Solvency
ILMN has an Altman-Z score of 4.67. This indicates that ILMN is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of ILMN (4.67) is better than 75.44% of its industry peers.
The Debt to FCF ratio of ILMN is 1.99, which is an excellent value as it means it would take ILMN, only 1.99 years of fcf income to pay off all of its debts.
ILMN has a Debt to FCF ratio of 1.99. This is amongst the best in the industry. ILMN outperforms 87.72% of its industry peers.
ILMN has a Debt/Equity ratio of 0.42. This is a healthy value indicating a solid balance between debt and equity.
ILMN has a Debt to Equity ratio (0.42) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | 1.99 | ||
| Altman-Z | 4.67 |
ROIC/WACC1.52
WACC10.81%
2.3 Liquidity
ILMN has a Current Ratio of 1.43. This is a normal value and indicates that ILMN is financially healthy and should not expect problems in meeting its short term obligations.
ILMN has a Current ratio of 1.43. This is in the lower half of the industry: ILMN underperforms 77.19% of its industry peers.
ILMN has a Quick Ratio of 1.12. This is a normal value and indicates that ILMN is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of ILMN (1.12) is worse than 68.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 152.02% over the past year.
The earnings per share for ILMN have been decreasing by -17.93% on average. This is quite bad
ILMN shows a decrease in Revenue. In the last year, the revenue decreased by -2.32%.
Measured over the past years, ILMN shows a small growth in Revenue. The Revenue has been growing by 4.29% on average per year.
EPS 1Y (TTM)152.02%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%17.54%
Revenue 1Y (TTM)-2.32%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%0.37%
3.2 Future
ILMN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.95% yearly.
ILMN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.99% yearly.
EPS Next Y96.03%
EPS Next 2Y44.64%
EPS Next 3Y34.05%
EPS Next 5Y24.95%
Revenue Next Year-0.86%
Revenue Next 2Y0.68%
Revenue Next 3Y2.56%
Revenue Next 5Y3.99%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 33.59, which means the current valuation is very expensive for ILMN.
Based on the Price/Earnings ratio, ILMN is valued a bit cheaper than 68.42% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.25, ILMN is valued a bit more expensive.
ILMN is valuated quite expensively with a Price/Forward Earnings ratio of 28.57.
ILMN's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. ILMN is cheaper than 71.93% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.98. ILMN is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.59 | ||
| Fwd PE | 28.57 |
4.2 Price Multiples
78.95% of the companies in the same industry are more expensive than ILMN, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, ILMN is valued cheaply inside the industry as 85.96% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.38 | ||
| EV/EBITDA | 19.76 |
4.3 Compensation for Growth
ILMN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of ILMN may justify a higher PE ratio.
A more expensive valuation may be justified as ILMN's earnings are expected to grow with 34.05% in the coming years.
PEG (NY)0.35
PEG (5Y)N/A
EPS Next 2Y44.64%
EPS Next 3Y34.05%
5. Dividend
5.1 Amount
ILMN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:ILMN (1/13/2026, 3:48:59 PM)
146.435
+0.88 (+0.61%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners104.7%
Inst Owner Change0.59%
Ins Owners0.17%
Ins Owner Change-0.21%
Market Cap22.38B
Revenue(TTM)4.29B
Net Income(TTM)703.00M
Analysts73.33
Price Target126.28 (-13.76%)
Short Float %4.86%
Short Ratio4.17
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.9%
Min EPS beat(2)12.52%
Max EPS beat(2)15.27%
EPS beat(4)3
Avg EPS beat(4)5.34%
Min EPS beat(4)-7.76%
Max EPS beat(4)15.27%
EPS beat(8)6
Avg EPS beat(8)97.15%
EPS beat(12)10
Avg EPS beat(12)231.96%
EPS beat(16)13
Avg EPS beat(16)178.01%
Revenue beat(2)0
Avg Revenue beat(2)-0.74%
Min Revenue beat(2)-1.21%
Max Revenue beat(2)-0.28%
Revenue beat(4)0
Avg Revenue beat(4)-0.66%
Min Revenue beat(4)-1.21%
Max Revenue beat(4)-0.18%
Revenue beat(8)3
Avg Revenue beat(8)-0.29%
Revenue beat(12)4
Avg Revenue beat(12)-0.57%
Revenue beat(16)5
Avg Revenue beat(16)-0.78%
PT rev (1m)2.26%
PT rev (3m)10.92%
EPS NQ rev (1m)-0.06%
EPS NQ rev (3m)3.08%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)4.26%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.72%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.59 | ||
| Fwd PE | 28.57 | ||
| P/S | 5.22 | ||
| P/FCF | 22.38 | ||
| P/OCF | 19.94 | ||
| P/B | 9.4 | ||
| P/tB | 21.45 | ||
| EV/EBITDA | 19.76 |
EPS(TTM)4.36
EY2.98%
EPS(NY)5.13
Fwd EY3.5%
FCF(TTM)6.54
FCFY4.47%
OCF(TTM)7.34
OCFY5.01%
SpS28.06
BVpS15.58
TBVpS6.83
PEG (NY)0.35
PEG (5Y)N/A
Graham Number39.1
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.38% | ||
| ROE | 29.53% | ||
| ROCE | 20.76% | ||
| ROIC | 16.4% | ||
| ROICexc | 23.54% | ||
| ROICexgc | 43.23% | ||
| OM | 20.41% | ||
| PM (TTM) | 16.39% | ||
| GM | 66.74% | ||
| FCFM | 23.32% |
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-6.48%
ROICexc growth 3YN/A
ROICexc growth 5Y-9.28%
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
F-Score7
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | 1.99 | ||
| Debt/EBITDA | 0.86 | ||
| Cap/Depr | 44.36% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 97.57% | ||
| Profit Quality | 142.25% | ||
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.12 | ||
| Altman-Z | 4.67 |
F-Score7
WACC10.81%
ROIC/WACC1.52
Cap/Depr(3y)66.6%
Cap/Depr(5y)76.75%
Cap/Sales(3y)5.82%
Cap/Sales(5y)5.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)152.02%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%17.54%
EPS Next Y96.03%
EPS Next 2Y44.64%
EPS Next 3Y34.05%
EPS Next 5Y24.95%
Revenue 1Y (TTM)-2.32%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%0.37%
Revenue Next Year-0.86%
Revenue Next 2Y0.68%
Revenue Next 3Y2.56%
Revenue Next 5Y3.99%
EBIT growth 1Y154.36%
EBIT growth 3YN/A
EBIT growth 5Y-7.67%
EBIT Next Year36.79%
EBIT Next 3Y17.14%
EBIT Next 5Y16.22%
FCF growth 1Y495.24%
FCF growth 3Y28.14%
FCF growth 5Y-3.38%
OCF growth 1Y179.8%
OCF growth 3Y15.37%
OCF growth 5Y-4.45%
ILLUMINA INC / ILMN FAQ
Can you provide the ChartMill fundamental rating for ILLUMINA INC?
ChartMill assigns a fundamental rating of 5 / 10 to ILMN.
Can you provide the valuation status for ILLUMINA INC?
ChartMill assigns a valuation rating of 6 / 10 to ILLUMINA INC (ILMN). This can be considered as Fairly Valued.
How profitable is ILLUMINA INC (ILMN) stock?
ILLUMINA INC (ILMN) has a profitability rating of 7 / 10.
What is the financial health of ILLUMINA INC (ILMN) stock?
The financial health rating of ILLUMINA INC (ILMN) is 5 / 10.
What is the expected EPS growth for ILLUMINA INC (ILMN) stock?
The Earnings per Share (EPS) of ILLUMINA INC (ILMN) is expected to grow by 96.03% in the next year.